Hepatitis C virus-related cirrhosis: Is antiviral treatment mandatory?;Faut-il traiter par les antiviraux les malades atteints de cirrhose virale C?

Gastroenterologie Clinique et Biologique

Volumn 25, Issue 5, 2001, Pages 509-513

  Castera, Laurent ^a   Roulot, Dominique ^a   Trinchet, Jean Claude ^b   Beaugrand, Michel ^b  

^a HÔPITAL JEAN VERDIER   (France)

^b AVICENNE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; RIBAVIRIN;

DISEASE COURSE; DRUG EFFICACY; EUROPE; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; LIVER CIRRHOSIS; MORTALITY; NONHUMAN; REVIEW;

ANTIVIRAL AGENTS; HEPATITIS C; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; NEUTROPENIA; THROMBOCYTOPENIA;

EID: 0034904854     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Hepatitis C virus related cirrhosis: Time to occurrence of hepatocellular carcinoma and death
2. Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients
3. The long-term outcomes of patients with compensated hepatitis C virus- related cirrhosis and history of parenteral exposure in the United States
4. Determinants of outcome of compensated hepatitis C virus-related cirrhosis
5. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C
6. La transplantation hépatique en France: État présent et à venir vu de l'établissement français des greffes
7. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy
8. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy
9. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C
10. National Institutes of Health Consensus Development Conference Panel statement: Management of hepatitis C
11. EASL International Consensus Conference on hepatitis C. Paris, 26-27 February 1999. Consensus statement
12. Cirrhose: Toujours?
13. Réversibilité des cirrhoses virales C
14. Peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C: A 24 week treatment analysis of a multicenter, multinational phase III randomized controlled trial
15. Interferon treatment of cirrhotic patients with chronic hepatitis C
16. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
17. Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: Analysis of individual patient data of six controlled trials
18. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis
19. Peginterferon alfa-2a in patients with chronic hepatitis C
20. Efficacy of interferon treatment for patients with chronic hepatitis C: Comparison of response in cirrhotics, fibrotics, or nonfibrotics
21. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C
22. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis
23. Treatment of hepatitis C virus-related cirrhosis: A randomized, controlled trial of interferon alfa-2b versus no treatment
24. Espoirs de prophylaxie du carcinome hépatocellulaire par l'interféron-alpha au cours de la cirrhose virale
25. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: An evidence-based approach
26. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis
27. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B
28. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C
29. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C
30. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV- related liver cirrhosis
31. Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan
32. Hepatitis C virus resistance to antiviral therapy
33. Embolisation splénique partielle dans le traitement de l'hypersplénisme des patients atteints de cirrhose
34. Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: A meta-analysis of controlled and uncontrolled trials
35. Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C
36. Petit carcinome hépatocellulaire isolé chez les patients atteints d'une cirrhose classée Chil-Pugh A: Facteurs pronostiques chez 142 patients
37. La co-infection par les virus de l'hépatite C et de l'immunodéficience humaine à l'ère des multithérapies antirétrovirales
38. Efficacy and safety of combination therapy with interferon-alpha2b and ribavirin for chronic hepatitis C in HIV-infected patients
39. Safety and efficacy of interferon-ribavirin combination therapy in HCV- HIV coinfected subjects: An early report
40. Severe hepatitis in three AIDS patients treated with indinavir
41. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: A retrospective cohort study